{"id":"apvo101","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"APVO101 simultaneously targets programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, removing inhibitory signals that tumors exploit to evade immune detection. By blocking both checkpoints, the drug aims to achieve greater T-cell activation and proliferation compared to single-agent checkpoint inhibition, potentially improving anti-tumor efficacy in solid tumors.","oneSentence":"APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:18.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IB1001","Recombinant factor IX","IXINITY"],"phase":"phase_3","status":"active","brandName":"APVO101","genericName":"APVO101","companyName":"Medexus Pharma, Inc.","companyId":"medexus-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}